Rapamycin: the most-studied longevity drug in biology, and what it means for dogs and cats

In 1964, a Canadian expedition collected soil samples from Easter Island — Rapa Nui to its inhabitants. A bacterium in that soil produced a compound that would eventually be named after the island. It was developed as an antifungal, repurposed as an immunosuppressant for transplant patients, and then, decades later, turned out to be the most reliable pharmacological way anyone has found to extend the lifespan of a mammal.

That is a strange history, and it explains most of the confusion around this drug.

What mTOR actually is

Every cell runs a nutrient sensor. When food is plentiful, that sensor tells the cell: grow. Build proteins, divide, expand. When food is scarce, the sensor quiets and the cell switches to a different mode: repair. Break down damaged proteins, recycle worn-out organelles, clean house. That second process is autophagy, and it is one of the deepest maintenance systems in biology.

The sensor is called mTOR — mechanistic target of rapamycin. It got that name because rapamycin was how scientists found it.

The theory of aging that follows is almost embarrassingly simple. In a world of constant abundance, the growth signal never switches off. Cells keep building and never clean up. Damage accumulates. Rapamycin turns the growth signal down, and the cleanup crew goes back to work.

The mouse data is not a rumor

Longevity claims usually deserve suspicion. This one has survived the kind of scrutiny that kills most of them.

In 2009, the NIA Interventions Testing Program — a program specifically designed to be hard to fool, running the same protocol across three independent laboratories — reported that rapamycin extended both median and maximal lifespan in genetically heterogeneous mice. The extraordinary part was the timing: dosing began at 600 days of age, roughly the equivalent of starting a human on a drug at 60 (Harrison et al., Nature, 2009).

Nearly everything else that extends lifespan in mice has to start early. This one worked when started late, and it replicated across three sites. That combination is why the field pivoted.

Later work found that even a transient course — a few months in middle age — produced a durable effect (Bitto et al., eLife, 2016). You may not need to take it forever. That single finding is why veterinary protocols are built around intermittent, low dosing rather than a daily pill for life.

The dose objection — and why it is the whole story

Here is where most coverage of rapamycin goes wrong.

"Rapamycin is an immunosuppressant" is a true sentence and a misleading one. At the high, continuous doses used to stop a transplant patient from rejecting a kidney, it suppresses the immune system. That is the entire point of the drug in that context.

At low, intermittent doses, something closer to the opposite appears to happen. In a randomized trial in adults over 65, six weeks of low-dose mTOR inhibition before a flu shot improved the antibody response and reduced the accumulation of exhausted immune cells (Mannick et al., Science Translational Medicine, 2014). A follow-up trial in over 600 older adults found low-dose TORC1 inhibition reduced the rate of respiratory infections (Mannick et al., 2018).

Fewer real infections, in real people. Not a biomarker — an outcome.

Same molecule. Different dose, different schedule, different pharmacology. If you take one thing from this article, take that.

The dog evidence

This is the part that makes rapamycin different from every other compound in this library: somebody ran the trial in the actual species.

In 2017, a randomized, placebo-controlled trial gave low-dose rapamycin to 24 middle-aged companion dogs — real pets, living in real homes, not laboratory animals. Over ten weeks the drug was well tolerated, with no significant excess of adverse events over placebo, and echocardiography showed improvements in age-associated measures of heart function (Urfer et al., GeroScience, 2017).

Twenty-four dogs and ten weeks is a small, short trial. It was never designed to prove lifespan extension, and it did not. What it did was establish tolerability well enough to justify the trial everyone is actually waiting for.

That trial is TRIAD — the Test of Rapamycin In Aging Dogs — a double-blind, placebo-controlled study in several hundred older companion dogs, run by the Dog Aging Project. It is the largest randomized test of a longevity drug ever conducted in companion animals.

It has not reported. Anyone telling you what TRIAD proved is telling you something they do not know. When it reads out, it will be the most important result this field has produced — in whichever direction it lands.

And cats?

Cats are chronically understudied, and it matters here more than usual, because cats are not small dogs. Their liver enzymes differ. Compounds that are unremarkable in a dog can be dangerous in a cat.

The good news is that somebody did the work. The RAPACAT trial — randomized, double-blind, placebo-controlled — tested once-weekly delayed-release rapamycin in cats with subclinical hypertrophic cardiomyopathy, and found it well tolerated at the doses studied. It was a safety and tolerability trial, not a lifespan trial, and it should be read as exactly that.

It is thin evidence. It is also real evidence, in cats, which is more than can be said for most of what gets marketed to cat owners.

What a careful reader should conclude

Let me be precise about the state of play, because precision is the point of this site.

• Established: rapamycin extends lifespan in mice, replicated, when started in middle age.
• Established: low, intermittent dosing improves markers of immune function in older humans and reduces infections — it does not simply suppress immunity the way transplant dosing does.
• Established: short-course, low-dose rapamycin was well tolerated in a small randomized trial of pet dogs, with a cardiac signal worth following.
• Not established: that rapamycin extends the lifespan of dogs or cats. The trial designed to answer that question is still running.

That last line is not a hedge. It is the single most important sentence in this article, and it is the one most likely to be left out of anything trying to sell you something.

The practical part

Rapamycin is a prescription drug. It is not a supplement, it is not a nutraceutical, and it is not something to source from an unregulated seller and dose by guesswork against a body-weight chart you found online. Dose, schedule, drug interactions, and the decision to treat at all belong to a veterinarian who has examined your animal.

What you can do is read the literature yourself. Every study cited here is in the study library, with what it found, in which species, at what sample size — and an honest note on where the evidence runs out.

Not veterinary advice. Not intended to diagnose, treat, cure, or prevent any disease. Talk to your veterinarian.

References

1. Harrison D.E. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 2009. Find on PubMed
2. Bitto A. et al. Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. eLife, 2016. Find on PubMed
3. Urfer S.R. et al. A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. GeroScience, 2017. Find on PubMed
4. Mannick J.B. et al. mTOR inhibition improves immune function in the elderly. Science Translational Medicine, 2014. Find on PubMed
5. Mannick J.B. et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Science Translational Medicine, 2018. Find on PubMed
6. Creevy K.E. et al. An open science study of ageing in companion dogs. Nature, 2022. Find on PubMed
7. Dog Aging Project — TRIAD. dogagingproject.org